Compare McKesson Corporation (MCK) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Oracle Corporation — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while Oracle Corporation trades at $127.95 (market cap $349.63B). The key difference: Oracle Corporation is far larger — about 3.6× McKesson Corporation's market cap, and Oracle Corporation pays the higher dividend (1.65%). Which is the better fit depends on your goals.
| MCK | ORCL | |
|---|---|---|
Market Cap | $97.35B | $349.63B |
Sector | Health | Technology |
52-Week High | $995.69 | $328.33 |
52-Week Low | $659.01 | $121.37 |
Enterprise Value | $101.98B | $478.88B |
Dividend Yield | 0.39% | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
Oracle (ORCL) trades at $126.48, up 1.78% today, with a strong fundamental backdrop including revenue growth to $57.40B in 2025 and a net income margin of 25.37%. Recent quarters have consistently beaten EPS estimates, and analyst consensus is bullish with a $253.30 price target. Technicals show a bearish overall signal but with bullish oscillators, and the stock faces support near $125.
The outlook is positive given Oracle's AI infrastructure expansion and earnings momentum, but risks include high debt levels and competitive pressures. The stock offers growth potential if execution continues, yet investors should weigh valuation multiples against sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
